Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
52°
Rain
Toggle navigation
Menu
Subscribe
Home
News
Local News
Sports
Entertainment
Obituaries
Photos
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Clovis Oncology Inc
(NQ:
CLVS
)
8.410
USD
+0.200 (+2.44%)
Streaming Delayed Price
Updated: 4:01 AM EST, Jan 27, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Clovis Oncology Inc
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Clovis Oncology Announces Preliminary Product Revenues for the Fourth Quarter and Full Year 2020
January 11, 2021
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended December 31, 2020. The financial information presented...
From
Business Wire News Releases
Clovis Oncology Submits Investigational New Drug Applications for Novel Peptide-Targeted Radionuclide FAP-2286 for Therapeutic and Imaging Clinical Trial
December 29, 2020
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the company has completed submission of two Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) for...
From
Business Wire News Releases
Thinking about buying stock in Agios Pharmaceuticals, Clovis Oncology, Aqua Metals, Cocrystal Pharma, or Luminar Technologies?
December 21, 2020
InvestorsObserver issues critical PriceWatch Alerts for AGIO, CLVS, AQMS, COCP, and LAZR.
From
PR Newswire
Clovis Oncology’s Rubraca® (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ova
December 21, 2020
Clovis Oncology, Inc. (NASDAQ: CLVS), today announced topline data from the randomized Phase 3 ARIEL4 study of Rubraca, which met its primary endpoint of improved investigator-assessed progression-free...
From
Business Wire News Releases
Clovis Oncology Announces Exercise by Existing Holder of Option to Purchase an Additional $7.5 Million Aggregate Principal Amount of the Company’s 4.50% Convertible Senior Notes Due 2024
November 24, 2020
Clovis Oncology Announces Exercise by Existing Holder of Option to Purchase an Additional $7.5 Million Aggregate Principal Amount of the Company’s 4.5
From
Business Wire News Releases
Clovis Oncology to Present at the Piper Sandler 32nd Annual Healthcare Conference
November 20, 2020
Clovis Oncology to Present at the Piper Sandler 32nd Annual Healthcare Conference
From
Business Wire News Releases
Clovis Oncology Announces Third Quarter 2020 Operating Results
November 05, 2020
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2020, and provided an update on the Company’s clinical development programs and regulatory and...
From
Business Wire News Releases
Clovis Oncology Announces Debt Exchange Transaction and Offering of Convertible Senior Notes
November 05, 2020
Clovis Oncology Announces Debt Exchange Transaction and Offering of Convertible Senior Notes
From
Business Wire News Releases
Clovis Oncology to Announce Third Quarter 2020 Financial Results and Host Webcast Conference Call on November 5
October 20, 2020
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2020 financial results on Thursday, November 5, 2020, before the open of the U.S. financial markets. Clovis’ senior management will...
From
Business Wire News Releases
Global Brain Tumor Therapeutics Market Projected to Exceed $2.70 Billion By 2023
October 01, 2020
Tags
Featured News
From
FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Global Brain Tumor Therapeutics Market Projected to Exceed $2.70 Billion By 2023
October 01, 2020
Financialnewsmedia.com News Commentary
From
PR Newswire
New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline
September 17, 2020
New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline
From
Business Wire News Releases
Clovis Oncology Announces Oral Plenary Session Presentation at International Gynecologic Cancer Society (IGCS) Digital Annual Global Meeting
September 10, 2020
Clovis Oncology Announces Oral Plenary Session Presentation at International Gynecologic Cancer Society (IGCS) Digital Annual Global Meeting
From
Business Wire News Releases
Clovis Oncology to Highlight Data for its Three Portfolio Compounds at the ESMO Virtual Congress 2020
September 09, 2020
Clovis Oncology to Highlight Data for its Three Portfolio Compounds at the ESMO Virtual Congress 2020
From
Business Wire News Releases
Clovis Oncology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 08, 2020
Clovis Oncology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
From
Business Wire News Releases
FDA Approves FoundationOne® Liquid CDx to Serve as Rubraca® (rucaparib) Companion Diagnostic to Identify Eligible Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
August 26, 2020
FDA Approves FoundationOne® Liquid CDx to Serve as Rubraca® (rucaparib) Companion Diagnostic to Identify Eligible Patients with BRCA1/2-Mutant, mCRPC
From
Business Wire News Releases
Clinical Trials Testing New Paradigms For Advanced Therapies Treating Metastatic Cancer Conditions
August 20, 2020
Tags
Featured News
From
FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Clinical Trials Testing New Paradigms For Advanced Therapies Treating Metastatic Cancer Conditions
August 20, 2020
Financialnewsmedia.com News Commentary
From
PR Newswire
Thinking about buying stock in NovaBay Pharmaceuticals, RISE Education, eMagin Corp, Avinger Inc, or Clovis Oncology?
August 18, 2020
InvestorsObserver issues critical PriceWatch Alerts for NBY, REDU, EMAN, AVGR, and CLVS.
From
PR Newswire
Journal of Clinical Oncology Publishes Additional Data from Clovis Oncology’s TRITON2 Clinical Trial Evaluating Rubraca® (rucaparib) for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations
August 17, 2020
JCO Publishes Additional Data from CLVS TRITON2 Clinical Trial Evaluating Rubraca® for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations
From
Business Wire News Releases
Clovis Oncology Announces Second Quarter 2020 Operating Results
August 06, 2020
Clovis Oncology Announces Second Quarter 2020 Operating Results
From
Business Wire News Releases
Clovis Oncology Announces First Patient Enrolled in the Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in Gynecologic Cancers
August 05, 2020
Clovis Oncology Announces First Patient Enrolled in the Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in ...
From
Business Wire News Releases
Clovis Oncology to Announce Second Quarter 2020 Financial Results and Host Webcast Conference Call on August 6
July 23, 2020
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2020 financial results on Thursday, August 6, 2020, after the close of the U.S. financial markets. Clovis’ senior management will...
From
Business Wire News Releases
Why Developments for Targeted Therapies Are Expected to Drive Sales for Brain Tumor Drug Market
July 08, 2020
Tags
Featured News
From
FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Why Developments for Targeted Therapies Are Expected to Drive Sales for Brain Tumor Drug Market
July 08, 2020
Financialnewsmedia.com News Commentary
From
PR Newswire
Clinical Trials For New Therapies Providing Hope For Metastatic Breast Cancer Patients
June 23, 2020
Tags
Featured News
From
FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Clinical Trials for new Therapies Providing Hope for Metastatic Breast Cancer Patients
June 23, 2020
Financialnewsmedia.com News Commentary
From
PR Newswire
New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
June 22, 2020
- Combination Therapy Resulted in Durable, Dose-Dependent Antitumor Efficacy in a Preclinical Model of Colon Cancer -
From
PR Newswire
Clovis Oncology to Highlight Rubraca® (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020
June 17, 2020
Clovis Oncology to Highlight Rubraca® (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020
From
Business Wire News Releases
Clovis Oncology Announces Completion of Target Enrollment in the ATHENA Trial, a Phase 3 Maintenance Treatment Study in Front-line, Newly-Diagnosed Advanced Ovarian Cancer
June 10, 2020
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the completion of target patient enrollment in the Clovis-sponsored Phase 3 ATHENA trial evaluating the combination of Clovis’ Rubraca® (rucaparib),...
From
Business Wire News Releases
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.